Jed Black Selected Research

solriamfetol

1/2022	Test-retest reliability of the Epworth Sleepiness Scale in clinical trial settings.
1/2020	Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
1/2020	Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.
1/2020	Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
1/2019	Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
1/2019	A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
1/2019	Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
10/2017	Identifying clinically important difference on the Epworth Sleepiness Scale: results from a narcolepsy clinical trial of JZP-110.
7/2017	Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes.
7/2016	Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jed Black Research Topics

Disease

37	Narcolepsy 01/2022 - 10/2002
15	Cataplexy 01/2022 - 10/2002
15	Sleepiness 01/2022 - 11/2004
15	Disorders of Excessive Somnolence (Hypersomnia) 01/2022 - 10/2002
10	Obstructive Sleep Apnea 01/2022 - 10/2002
7	Sleep Initiation and Maintenance Disorders (Insomnia) 08/2017 - 10/2002
5	Nausea 01/2019 - 05/2006
5	Headache (Headaches) 01/2019 - 05/2006
4	Sleep Apnea Syndromes (Sleep Apnea) 01/2019 - 01/2003
3	Nasopharyngitis 01/2019 - 01/2018
2	Muscle Weakness 01/2022 - 09/2005
2	Idiopathic Hypersomnia 01/2022 - 01/2022
2	Sleep Wake Disorders 01/2022 - 10/2002
2	Dizziness (Lightheadedness) 01/2018 - 05/2006
1	Enuresis 01/2018
1	Vomiting 01/2018
1	Psychotic Disorders (Schizoaffective Disorder) 01/2018
1	Diarrhea 07/2016
1	Airway Obstruction (Choking) 02/2013
1	Apnea 10/2008
1	Bradycardia 01/2007
1	Syncope (Fainting) 01/2007
1	Body Weight (Weight, Body) 05/2006
1	Fatigue 05/2006
1	Mood Disorders (Mood Disorder) 05/2006
1	Migraine Disorders (Migraine) 05/2006
1	Duodenal Ulcer (Curling's Ulcer) 05/2006
1	Ulcerative Colitis 05/2006
1	Fibromyalgia (Fibrositis) 01/2006
1	Sleep Deprivation 09/2005
1	Parkinson Disease (Parkinson's Disease) 10/2002
1	Prader-Willi Syndrome (Syndrome, Prader-Willi) 10/2002
1	Restless Legs Syndrome (Restless Legs) 10/2002
1	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 10/2002
1	Nervous System Diseases (Neurological Disorders) 10/2002

Drug/Important Bio-Agent (IBA)

24	Sodium Oxybate (gamma Hydroxybutyrate)FDA Link 01/2022 - 11/2004
10	solriamfetolIBA 01/2022 - 07/2016
8	Modafinil (Provigil)FDA Link 01/2020 - 01/2003
5	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2020 - 02/2017
5	OrexinsIBA 08/2017 - 10/2002
4	Dopamine (Intropin)FDA LinkGeneric 01/2020 - 01/2019
4	Pharmaceutical PreparationsIBA 01/2018 - 05/2006
3	SolutionsIBA 01/2022 - 01/2018
2	NexusIBA 01/2021 - 01/2021
2	almorexantIBA 08/2017 - 02/2017
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Serotonin (5 Hydroxytryptamine)IBA 02/2017
1	Orexin Receptor AntagonistsIBA 02/2017
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 02/2017
1	BenzodiazepinesIBA 02/2017
1	Hypnotics and Sedatives (Sedatives)IBA 02/2017
1	Anti-Anxiety Agents (Anxiolytics)IBA 02/2017
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 02/2017
1	Oxygen (Dioxygen)IBA 10/2008
1	indiplonIBA 06/2007
1	Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone (FCCP)IBA 02/2007
1	HLA-DQ Antigens (HLA-DQ)IBA 10/2002
1	Psychotropic Drugs (Psychoactive Drugs)IBA 10/2002
1	HLA-DQB1 antigen (HLA DQB1)IBA 10/2002
1	Biological ProductsIBA 10/2002

Therapy/Procedure

10	Therapeutics 01/2022 - 12/2002
3	Continuous Positive Airway Pressure 09/2013 - 05/2006
1	Oral Administration 02/2017
1	Plasmapheresis 09/2005